Eliana C Martinez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3992843/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Targeting mAKAPÎ ² expression as a therapeutic approach for ischemic cardiomyopathy. Gene Therapy, 2023, 30, 543-551.	2.3	4
2	FGF21-FGFR4 signaling in cardiac myocytes promotes concentric cardiac hypertrophy in mouse models of diabetes. Scientific Reports, 2022, 12, 7326.	1.6	8
3	Soluble Klotho, a biomarker and therapeutic strategy to reduce bronchopulmonary dysplasia and pulmonary hypertension in preterm infants. Scientific Reports, 2020, 10, 12368.	1.6	22
4	Signalosome-Regulated Serum Response Factor Phosphorylation Determining Myocyte Growth in Width Versus Length as a Therapeutic Target for Heart Failure. Circulation, 2020, 142, 2138-2154.	1.6	23
5	Calcineurin Aβ–Specific Anchoring Confers Isoform-Specific Compartmentation and Function in Pathological Cardiac Myocyte Hypertrophy. Circulation, 2020, 142, 948-962.	1.6	9
6	Neonatal hyperoxia exposure induces aortic biomechanical alterations and cardiac dysfunction in juvenile rats. Physiological Reports, 2020, 8, e14334.	0.7	13
7	Plasma Ceramides as Prognostic Biomarkers and Their Arterial and Myocardial Tissue Correlates in AcuteÂMyocardial Infarction. JACC Basic To Translational Science, 2018, 3, 163-175.	1.9	64
8	MicroRNA-31 promotes adverse cardiac remodeling and dysfunction in ischemic heart disease. Journal of Molecular and Cellular Cardiology, 2017, 112, 27-39.	0.9	46
9	RSK3 is required for concentric myocyte hypertrophy in an activated Raf1 model for Noonan syndrome. Journal of Molecular and Cellular Cardiology, 2016, 93, 98-105.	0.9	7
10	RSK3: A regulator of pathological cardiac remodeling. IUBMB Life, 2015, 67, 331-337.	1.5	16
11	Microcapsules engineered to support mesenchymal stem cell (MSC) survival and proliferation enable long-term retention of MSCs in infarcted myocardium. Biomaterials, 2015, 53, 12-24.	5.7	86
12	GYY4137 attenuates remodeling, preserves cardiac function and modulates the natriuretic peptide response to ischemia. Journal of Molecular and Cellular Cardiology, 2015, 87, 27-37.	0.9	39
13	An autologous platelet-rich plasma hydrogel compound restores left ventricular structure, function and ameliorates adverse remodeling in a minimally invasive large animal myocardial restoration model: A translational approach. Biomaterials, 2015, 45, 27-35.	5.7	42
14	Natriuretic peptide receptor 3 (NPR3) is regulated by microRNA-100. Journal of Molecular and Cellular Cardiology, 2015, 82, 13-21.	0.9	29
15	Incorporation of a Prolyl Hydroxylase Inhibitor into Scaffolds: A Strategy for Stimulating Vascularization. Tissue Engineering - Part A, 2015, 21, 1106-1115.	1.6	1
16	Post-ischaemic angiogenic therapy usingin vivoprevascularized ascorbic acid-enriched myocardial artificial grafts improves heart function in a rat model. Journal of Tissue Engineering and Regenerative Medicine, 2013, 7, 203-212.	1.3	8
17	Grafts Enriched with Subamnion-Cord-Lining Mesenchymal Stem Cell Angiogenic Spheroids Induce Post-Ischemic Myocardial Revascularization and Preserve Cardiac Function in Failing Rat Hearts. Stem Cells and Development, 2013, 22, 3087-3099.	1.1	25
18	Cord Lining-Mesenchymal Stem Cells Graft Supplemented with an Omental Flap Induces Myocardial Revascularization and Ameliorates Cardiac Dysfunction in a Rat Model of Chronic Ischemic Heart Failure. Tissue Engineering - Part A, 2013, 19, 1303-1315.	1.6	28

ELIANA C MARTINEZ

#	Article	IF	CITATIONS
19	Erratum to "Myocardial Restoration: Is It the Cell or the Architecture or Both?― Cardiology Research and Practice, 2012, 2012, 1-1.	0.5	18
20	Myocardial Restoration: Is It the Cell or the Architecture or Both?. Cardiology Research and Practice, 2012, 2012, 1-11.	0.5	9
21	Adult stem cells for cardiac tissue engineering. Journal of Molecular and Cellular Cardiology, 2011, 50, 312-319.	0.9	60
22	Off-Pump Coronary Bypass Surgery Is Safe in Patients with a Low Ejection Fraction (â‰ 2 5%). Heart Surgery Forum, 2010, 13, E136-E142.	0.2	9
23	Off-pump coronary artery bypass is a safe option in patients presenting as emergency. Annals of the Academy of Medicine, Singapore, 2010, 39, 607-12.	0.2	2
24	Myocardial tissue engineering: the quest for the ideal myocardial substitute. Expert Review of Cardiovascular Therapy, 2009, 7, 921-928.	0.6	24
25	Off-pump coronary bypass grafting is safe and efficient in patients with left main disease and higher EuroScoreâ~†. European Journal of Cardio-thoracic Surgery, 2009, 36, 616-620.	0.6	15
26	First paediatric left ventricular assist device implantation as bridge-to-recovery in Singapore. Annals of the Academy of Medicine, Singapore, 2009, 38, 649-2.	0.2	0
27	Determinants of Bioartificial Myocardial Graft Survival and Engraftment In Vivo. Journal of Heart and Lung Transplantation, 2008, 27, 1242-1250.	0.3	4
28	Consequences of incomplete repair of acute type A aortic dissection. Interactive Cardiovascular and Thoracic Surgery, 2008, 7, 1121-1123.	0.5	0
29	Novel Injectable Bioartificial Tissue Facilitates Targeted, Less Invasive, Large-Scale Tissue Restoration on the Beating Heart After Myocardial Injury. Circulation, 2005, 112, 1173-7.	1.6	213
30	Interdependent Serotonin Transporter and Receptor Pathways Regulate S100A4/Mts1, a Gene Associated With Pulmonary Vascular Disease. Circulation Research, 2005, 97, 227-235.	2.0	147
31	Epidermal Growth Factor Receptor Blockade Mediates Smooth Muscle Cell Apoptosis and Improves Survival in Rats With Pulmonary Hypertension. Circulation, 2005, 112, 423-431.	1.6	237
32	Electron microscopic study of actin polymerization in airway smooth muscle. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2004, 286, L1161-L1168.	1.3	66